TCB-008

N/A

Report date: 2025/10/02 20:00:08

Base Information

Drug NameTCB-008

Drug Alias NameGamma delta T cell lymphocyte(TC Biopharm)Allogeneic gamma delta T-lymphocytes TCB-008(TC Biopharm)Allogeneic γδ T-lymphocytes TCB-008(TC Biopharm)TCB-008

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTC BioPharm (Holdings) Plc

China Registration ClassN/A

Develop Information

Active CompaniesTc Biopharm Ltd

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A